Imaging for treatment optimization in advanced prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on the use of SPECT imaging to evaluate the pharmacokinetics and dosimetry of radiopharmaceutical therapies in patients with advanced prostate cancer and other advanced cancers. The study aims to validate quantitative SPECT image reconstruction methods and explore the relationship between dosimetry from SPECT images and patient outcomes. A total of 80 patients will undergo SPECT/CT imaging during their treatment, with each participant imaged three times after specific cycles of therapy. The goal is to improve the understanding of radiation distribution and its effects on both tumors and normal tissues.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Cohort A: Patients with advanced prostate cancer planning to undergo treatment with Radium-223
* Cohort B: Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617

  \*\*Eligible patients may be planning to undergo these treatments as part of standard of care or as part of another research protocol
* Age \> 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
* Histologic confirmation of malignancy

Exclusion Criteria:

* Patient is participating in another research protocol that does not allow participation in this imaging protocol or that has schedule of procedures that would not be compatible with this protocol.
* Patient unable to tolerate SPECT scan time, scan frequency, or position.

Where it's running

• Johns Hopkins University
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Ana Kiess, MD, PhD — Johns Hopkins University
• Study coordinator: Ana Kiess
• Email: akiess1@jhmi.edu
• Phone: 443-287-7528

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating AGX101 for advanced solid tumors

  This study is testing a new drug called AGX101 to see if it can help people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 7 sites Phase 1 Angiex, Inc. · Los Angeles, California and 6 other locations · NCT06440005

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.